Monoclonal Antibodies for Oncology: Global Markets

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,500	124 Pages	BCC Research	June, 2022	WA17244609

Best Price Guarantee
Price	from $5,500
Length	124 Pages
Publisher	BCC Research
Published Date	June, 2022
SKU	WA17244609

Monoclonal Antibodies for Oncology: Global Markets

Report Scope:

The current report provides detailed exposure of global monoclonal antibodies for the oncology market. This report highlights the current and future market potential of monoclonal antibodies for oncology treatment and includes a detailed analysis of the market's drivers, challenges, and opportunities. The report also covers market projections to 2027 and market share for key market players. The report details the market share of monoclonal antibodies for oncology based on type and application. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides the impact of the COVID-19 pandemic on this market.

Report Includes:

- 25 data tables and 24 additional tables
- A brief general outlook of the global monoclonal antibodies for oncology market
- Analyses of the global market trends, with market revenue (sales data) for 2020 and 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the current and future market potential of monoclonal antibodies for oncology treatment, and areas of focus to forecast this market into various segments and sub-segments
- Evaluation of the actual market size for monoclonal antibodies in oncology treatment, forecasted growth trends, and corresponding market share analysis by type of antibody, application area, and region
- Technology assessment of the key drivers, restraints and opportunities that will shape the market over the next five years (2022 to 2027)
- In-depth information on increasing investments on R&D activities, key technology issues, industry specific challenges, major types of end-user markets, and COVID-19 implications on the progress of this market
- Review of the patent landscape and new developments in the market for monoclonal antibodies for oncology and associated clinical trials
- Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
- Company profiles of major players, including AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc, Pfizer Inc.

Companies Mentioned

AMGEN INC.
Astrazeneca Pharmaceuticals
BRISTOL-MYERS SQUIBB
ELI LILLY
F. Hoffmann-La Roche AG
GILEAD SCIENCES INC.
GLAXOSMITHKLINE
JOHNSON & JOHNSON
MERCK & CO. INC.
MERCK KGAA
PFIZER INC.
SANOFI S.A.
SEAGEN

Chapter 1 Introduction: Study Goals and Objectives; Reasons for Doing This Study; Scope of Report; Information Sources; Methodology; Geographic Breakdown; Analyst’s Credentials; BCC Custom Research; Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background: Monoclonal Antibodies; History of Monoclonal Antibodies; Advantages and Disadvantages of Monoclonal Antibodies; Monoclonal Antibodies in Oncology; Types of Monoclonal Antibodies
Chapter 4 Market Dynamics: Market Drivers; Increasing Incidence of Cancer; New Product Launches; Rising Healthcare Expenditures and Government Funding; Licensing and Collaboration Agreements; Market Barriers; Price Controls; Regulatory Approval Pressures; Entry of Biosimilars; Opportunities; Impact of COVID-19
Chapter 5 Market Breakdown by Type: Types of Monoclonal Antibodies for Oncology; Market Overview; Market Revenue; Global Market for Monoclonal Antibodies in Oncology by Type; Humanized Monoclonal Antibodies; Human Monoclonal Antibodies; Chimeric Monoclonal Antibodies
Chapter 6 Market Breakdown by Application: Overview; Lung Cancer; Market Size and Forecast; Breast Cancer; Market Size and Forecast; Colorectal Cancer; Market Size and Forecast; Blood Cancer; Market Size and Forecast; Other Cancers; Market Size and Forecast
Chapter 7 Market Breakdown by Region: Introduction; North America; U.S.; Canada; Europe; Germany; U.K.; France; Italy; Spain; Rest of Europe; Asia-Pacific; China; India; Japan; Rest of Asia-Pacific; Rest of the World; Market Size and Forecast
Chapter 8 Regulatory Aspects: New Approvals of Monoclonal Antibodies for Oncology; Recalls, Withdrawals, and Safety Alerts
Chapter 9 Patent Review/ New Developments: New Developments; Phase I Clinical Trials; Phase II Clinical Trials; Phase III Clinical Trials
Chapter 10 Competitive Landscape: Mergers, Acquisitions, and Collaborations; Company Market Shares
Chapter 11 Company Profiles: AMGEN INC.; ASTRAZENECA PHARMACEUTICALS; BRISTOL-MYERS SQUIBB; ELI LILLY; F. HOFFMANN-LA ROCHE AG; GLAXOSMITHKLINE; GILEAD SCIENCES INC.; JOHNSON & JOHNSON; MERCK & CO. INC.; MERCK KGAA; PFIZER INC.; SANOFI S.A.; SEAGEN
List of Tables: Summary Table A : Global Market for Monoclonal Antibodies in Oncology, Through 2027; Summary Table B : Global Market for Monoclonal Antibodies in Oncology, by Type, Through 2027; Table 1 : Evolution of Monoclonal Antibodies; Table 2 : Advantages and Disadvantages of Monoclonal Antibodies; Table 3 : Monoclonal Antibodies Approved for Oncology; Table 4 : Murine Monoclonal Antibodies; Table 5 : Chimeric Monoclonal Antibodies; Table 6 : Humanized Monoclonal Antibodies; Table 7 : Human Monoclonal Antibodies; Table 8 : Total Number of New Cases and Deaths Due to Various Cancers Globally, 2020; Table 9 : Funding, by Research Areas, 2020; Table 10 : Global Market for Monoclonal Antibodies in Oncology, by Type, Through 2027; Table 11 : Global Market for Humanized Monoclonal Antibodies in Oncology, by Region, Through 2027; Table 12 : Global Market for Human Monoclonal Antibodies in Oncology, by Region, Through 2027; Table 13 : Global Market for Chimeric Monoclonal Antibodies in Oncology, by Region, Through 2027; Table 14 : Global Market for Monoclonal Antibodies in Oncology, by Application, Through 2027; Table 15 : Global Market Market for Monoclonal Antibodies for Lung Cancer, by Region, Through 2027; Table 16 : Global Market Market for Monoclonal Antibodies for Breast Cancer, by Region, Through 2027; Table 17 : Global Market Market for Monoclonal Antibodies for Colorectal Cancer, by Region, Through 2027; Table 18 : Global Market Market for Monoclonal Antibodies for Blood Cancer, by Region, Through 2027; Table 19 : Numbers for All Cancers (Except Non-Melanoma Skin Cancer), 2020; Table 20 : Global Market for Monoclonal Antibodies for Other Types of Blood Cancer, by Region, Through 2027; Table 21 : Global Market for Monoclonal Antibodies in Oncology, by Region, Through 2027; Table 22 : North American Market for Monoclonal Antibodies in Oncology, by Country, Through 2027; Table 23 : Cancer Incidence and Mortality, Age Standardized Rate, per 100,000, by Cancer Type, EU Countries, 2020; Table 24 : European Market for Monoclonal Antibodies in Oncology, by Country, Through 2027; Table 25 : Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Country, Through 2027; Table 26 : Newly Approved Monoclonal Antibodies for Oncology, 2019-April 2022; Table 27 : Recalls, Withdrawals, and Safety Alerts, 2019-April 2022; Table 28 : Monoclonal Antibodies for Oncology in Phase I Clinical Trials; Table 29 : Monoclonal Antibodies for Oncology in Phase II Clinical Trials; Table 30 : Monoclonal Antibodies for Oncology in Phase III Clinical Trials; Table 31 : M&A: Pharmaceutical Companies; Table 32 : Sales of Blockbuster Monoclonal Antibodies for Oncology, 2021; Table 33 : Amgen: Financial Performance, 2019-2021; Table 34 : AstraZeneca: Financial Performance, 2019-2021; Table 35 : AstraZeneca: Business Segment; Table 36 : Bristol-Myers Squibb: Financial Performance, 2019-2021; Table 37 : Eli Lilly: Business Segments; Table 38 : Eli Lilly: Financial Performance, 2019-2021; Table 39 : F. Hoffmann-La Roche: Business Segments; Table 40 : F. Hoffmann-La Roche: Financial Performance, 2019-2021; Table 41 : Johnson & Johnson: Business Segments; Table 42 : Johnson & Johnson: Financial Performance, 2019-2021; Table 43 : Merck & Co. Inc.: Business Segment; Table 44 : Merck & Co. Inc.: Financial Performance, 2019-2021; Table 45 : Pfizer: Business Segment; Table 46 : Pfizer: Financial Performance, 2019-2021; Table 47 : Sanofi: Business Segments
List of Figures: Summary Figure A : Global Market for Monoclonal Antibodies in Oncology, 2020-2027; Summary Figure B : Global Market for Monoclonal Antibodies in Oncology, by Type, 2020-2027; Figure 1 : Approved Antibody Therapeutics in the U.S. and EU, 2010-2021; Figure 2 : Global Estimated New Cancer Cases, by Region, 2020 vs. 2040; Figure 3 : Global Market for Monoclonal Antibodies in Oncology, by Type, 2020-2027; Figure 4 : Global Market Shares of Monoclonal Antibodies in Oncology, by Type, 2021; Figure 5 : Global Market for Humanized Monoclonal Antibodies in Oncology, by Region, 2020-2027; Figure 6 : Global Market for Human Monoclonal Antibodies in Oncology, by Region, 2020-2027; Figure 7 : Global Market for Chimeric Monoclonal Antibodies in Oncology, by Region, 2020-2027; Figure 8 : Global Market for Monoclonal Antibodies in Oncology, by Application, 2020-2027; Figure 9 : Global Market Shares of Monoclonal Antibodies in Oncology, by Application, 2021; Figure 10 : Global Market for Monoclonal Antibodies for Lung Cancer, by Region, 2020-2027; Figure 11 : Global Market for Monoclonal Antibodies for Breast Cancer, by Region, 2020-2027; Figure 12 : Global Market for Monoclonal Antibodies for Colorectal Cancer, by Region, 2020-2027; Figure 13 : Global Market for Monoclonal Antibodies for Blood Cancer, by Region, 2020-2027; Figure 14 : Global Market for Monoclonal Antibodies for Other Types of Blood Cancer, by Region, 2020-2027; Figure 15 : Global Market for Monoclonal Antibodies in Oncology, by Region, 2020-2027; Figure 16 : Global Market Shares of Monoclonal Antibodies in Oncology, by Region, 2021; Figure 17 : North American Market for Monoclonal Antibodies in Oncology, by Country, 2020-2027; Figure 18 : U.S. Market for Monoclonal Antibodies in Oncology, 2020-2027; Figure 19 : Canadian Market for Monoclonal Antibodies in Oncology, 2020-2027; Figure 20 : European Market for Monoclonal Antibodies in Oncology, by Country, 2020-2027; Figure 21 : German Market for Monoclonal Antibodies in Oncology, 2020-2027; Figure 22 : U.K. Market for Monoclonal Antibodies in Oncology, 2020-2027; Figure 23 : French Market for Monoclonal Antibodies in Oncology, 2020-2027; Figure 24 : Italian Market for Monoclonal Antibodies in Oncology, 2020-2027; Figure 25 : Spanish Market for Monoclonal Antibodies in Oncology, 2020-2027; Figure 26 : Rest of European Market for Monoclonal Antibodies in Oncology, 2020-2027; Figure 27 : Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Country, 2020-2027; Figure 28 : Chinese Market for Monoclonal Antibodies in Oncology, 2020-2027; Figure 29 : Indian Market for Monoclonal Antibodies in Oncology, 2020-2027; Figure 30 : Japanese Market for Monoclonal Antibodies in Oncology, 2020-2027; Figure 31 : Rest of Asia-Pacific Market for Monoclonal Antibodies in Oncology, 2020-2027; Figure 32 : Rest of the World Market for Monoclonal Antibodies in Oncology, 2020-2027; Figure 33 : Global Manufacturer/Supplier Market Shares of Monoclonal Antibodies in Oncology, 2021; Figure 34 : Amgen: Annual Revenue, 2019-2021; Figure 35 : Amgen: Total Sales Share, by Product, 2021; Figure 36 : Amgen: Total Revenue Share, by Region, 2021; Figure 37 : AstraZeneca: Annual Revenue, 2019-2021; Figure 38 : AstraZeneca: Total Sales Share, by Segment, 2021; Figure 39 : AstraZeneca: Total Revenue Share, by Region, 2021; Figure 40 : Bristol-Myers Squibb: Annual Revenue, 2019-2021; Figure 41 : Bristol Myers Squibb: Total Sales Share, by Product, 2021; Figure 42 : Bristol-Myers Squibb: Total Revenue Share, by Region, 2021; Figure 43 : Eli Lilly: Annual Revenue, 2019-2021; Figure 44 : Eli Lilly: Total Sales Share, by Product Segment, 2021; Figure 45 : Eli Lilly: Total Revenue Share, by Region, 2021; Figure 46 : F. Hoffmann-La Roche: Annual Revenue, 2019-2021; Figure 47 : F. Hoffmann-La Roche: Total Sales Share, by Pharmaceutical Segment, 2021; Figure 48 : F. Hoffmann-La Roche: Total Revenue Share, by Region, 2021; Figure 49 : Johnson & Johnson: Annual Revenue, 2019-2021; Figure 50 : Johnson & Johnson: Total Sales Share, by Business Segment, 2021; Figure 51 : Johnson & Johnson: Total Revenue Share, by Region, 2021; Figure 52 : Merck & Co. Inc.: Annual Revenue, 2019-2021; Figure 53 : Merck & Co. Inc.: Revenue Share, by Business Segment, 2021; Figure 54 : Merck & Co. Inc.: Revenue Share, by Region, 2021; Figure 55 : Pfizer: Annual Revenue, 2019-2021; Figure 56 : Pfizer: Net Sales Share, by Business Segment, 2021; Figure 57 : Pfizer: Net Sales Share, by Region, 2021